First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

[1]  J. Tabernero,et al.  Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. , 2021, Future oncology.

[2]  W. Scheithauer,et al.  FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial , 2020, British Journal of Cancer.

[3]  E. Van Cutsem,et al.  Trifluridine/Tipiracil plus Bevacizumab in Patients with Untreated Metastatic Colorectal Cancer Ineligible for Intensive Therapy: the Randomized TASCO1 Study. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  A. Falcone,et al.  First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design. , 2020, Future oncology.

[5]  Y. Zöllner,et al.  Effect of age on the effectiveness of the first-line standard of care treatment in patients with metastatic colorectal cancer: systematic review of observational studies , 2019, Journal of Cancer Research and Clinical Oncology.

[6]  C. Punt,et al.  Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group. , 2019, Clinical colorectal cancer.

[7]  V. Gebski,et al.  Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial. , 2019, Clinical colorectal cancer.

[8]  C. Punt,et al.  Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  S. Barni,et al.  Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta‐Analysis , 2017, Clinical colorectal cancer.

[10]  E. Ricevuto,et al.  Clinical parameters to guide decision-making in elderly metastatic colorectal cancer patients treated with intensive cytotoxic and anti-angiogenic therapy , 2016, Oncotarget.

[11]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  H. Lenz,et al.  TAS-102, a novel antitumor agent: a review of the mechanism of action. , 2015, Cancer treatment reviews.

[13]  A. Beaudoin,et al.  Palliative chemotherapy for patients 70 years of age and older with metastatic colorectal cancer: a single-centre experience. , 2015, Current oncology.

[14]  T. Conroy,et al.  Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer , 2011, International journal of cancer.